PancreaSure

1. PancreaSure predicts early-stage pancreatic ductal adenocarcinoma in humans (77.5% sensitivity (95% CI 66.0–86.5); 93.6% specificity (95% CI 91.8–95.1)).

   “PancreaSure detected early-stage PDAC with 77.5% sensitivity (95% CI, 66.0-86.5) and 93.6% specificity (95% CI, 91.8-95.1), significantly outperforming predefined success criteria.”

   HumansIndividuals at high risk due to a pathogenic susceptibility variant or strong family historyserum

   The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective Secondary Analysis

   Journal of clinical medicine·22 Sep 2026

More on Early-stage pancreatic ductal adenocarcinoma